Skip to main content
Tuoxin Pharmaceutical Group Co.,Ltd. logo

Tuoxin Pharmaceutical Group Co.,Ltd. — Investor Relations & Filings

Ticker · 301089 ISIN · CNE100004YC3 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 734 across all filing types
Latest filing 2022-04-21 Audit Report / Informat…
Country CN China
Listing Shenzhen Stock Exchange 301089

About Tuoxin Pharmaceutical Group Co.,Ltd.

https://www.tuoxinpharm.com

Tuoxin Pharmaceutical Group Co., Ltd. specializes in the research, development, production, and distribution of nucleosides and nucleotides. The company serves as a major global supplier of active pharmaceutical ingredients (APIs) and chemical intermediates. Its core product portfolio includes cytidine, inosine, guanosine, adenosine, and their various derivatives, which are essential components in the synthesis of antiviral, anti-tumor, and cardiovascular medications. Notably, the group provides key intermediates for drugs such as Ribavirin and Azvudine. Tuoxin Pharmaceutical leverages advanced synthetic biotechnology and large-scale manufacturing capabilities to support the global pharmaceutical industry. The company maintains a focus on technological innovation and quality control to ensure the stability and purity of its chemical products for diverse therapeutic applications.

Recent filings

Filing Released Lang Actions
2021 年度内部控制自我评价报告
Audit Report / Information Classification · 95% confidence The document is titled '2021年度内部控制自我评价报告' which translates to '2021 Internal Control Self-Evaluation Report' for Xinxiang Tuoxin Pharmaceutical Co., Ltd. It is a detailed report on the company's internal control evaluation for the fiscal year ending December 31, 2021. The content includes evaluation conclusions, scope, methodology, risk assessments, control activities, and defect recognition and remediation related to internal controls. It is not an announcement or a brief summary but a comprehensive report on internal control self-assessment. This type of document fits the category of Audit Report / Information (AR), as it deals with internal control evaluation and related audit information, but is not a full Annual Report (10-K) or financial statement. The document length (11,709 characters) and detailed content confirm it is a full report, not a mere announcement or certification. Therefore, the appropriate classification is AR with high confidence. FY 2021
2022-04-21 Chinese
防范控股股东及关联方资金占用管理办法
Governance Information Classification · 95% confidence The document is titled as a management policy document "防范控股股东及关联方资金占用管理办法" (Measures to Prevent Fund Occupation by Controlling Shareholders and Related Parties) issued by 新乡拓新药业股份有限公司. It outlines internal rules, principles, responsibilities, and penalties related to preventing fund occupation by controlling shareholders and related parties. It references relevant laws and regulatory guidelines but does not contain financial statements, audit results, or financial performance data. It is a governance-related internal control document rather than a financial report, announcement, or regulatory filing. The document is not an announcement of a report but a detailed internal governance policy. Therefore, the most appropriate classification is Governance Information (CGR). The document length is 3724 characters, which is relatively short but contains substantive governance content, not just an announcement or certification.
2022-04-21 Chinese
控股股东及实际控制人行为规范
Governance Information Classification · 95% confidence The document is titled "新乡拓新药业股份有限公司 控股股东及实际控制人行为规范" which translates to "Behavioral Norms for Controlling Shareholders and Actual Controllers of Xinxiang Tuoxin Pharmaceutical Co., Ltd.". It is a detailed policy document outlining the rules, obligations, and governance practices for controlling shareholders and actual controllers, including sections on independence, information disclosure, share trading, control transfer, and commitments. The document references relevant laws and stock exchange rules, and it is a governance-related internal regulation rather than a financial report or announcement. It does not contain financial statements, earnings data, or audit information. It is not an announcement or a brief notice but a full policy document. Therefore, the most appropriate classification is Governance Information (CGR). The document length (7183 characters) supports it being a full report rather than a short announcement.
2022-04-21 Chinese
股东大会议事规则
Governance Information Classification · 95% confidence The document is titled "新乡拓新药业股份有限公司 股东大会议事规则" which translates to "Rules of Procedure for the Shareholders' General Meeting of Xinxiang Tuoxin Pharmaceutical Co., Ltd." It is a detailed procedural document outlining the rules, regulations, and processes for convening and conducting shareholders' meetings, including the rights and responsibilities of shareholders, board, and other parties. It does not contain financial statements, audit opinions, voting results, or announcements of meetings, but rather the internal governance rules related to shareholder meetings. This fits the definition of Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices. The document length is sufficient and the content is substantive, not merely an announcement or notice. Therefore, the correct classification is CGR with high confidence.
2022-04-21 Chinese
中天国富证券有限公司关于新乡拓新药业股份有限公司2021年度募集资金存放与使用情况的核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed verification opinion report by Zhongtian Guofu Securities Co., Ltd. regarding the 2021 annual fundraising funds deposit and usage situation of Xinxiang Tuoxin Pharmaceutical Co., Ltd. It includes specific data on fundraising amounts, usage, storage, investment projects, and compliance with regulatory requirements. It references regulatory rules and includes an auditor's verification opinion. The document is not an announcement of a report but contains substantive financial and operational data related to fundraising and capital usage. This matches the definition of an Audit Report / Information (AR), which covers standalone audit reports and applied accounting principles related to specific financial activities, excluding full annual reports. The document is 8282 characters long, which is sufficient for a detailed report rather than a brief announcement. Therefore, the appropriate classification is AR with high confidence. FY 2021
2022-04-21 Chinese
独立董事关于第四届董事会第十一次会议相关事项的独立意见
AGM Information Classification · 95% confidence The document is an independent opinion from the independent directors of a company regarding several proposals to be submitted to the 2021 annual general meeting (AGM). It discusses profit distribution, remuneration, internal control self-evaluation report, use of raised funds, and related party transactions. The document references the 2021 annual shareholders meeting and the submission of these proposals for shareholder approval. It is not the full annual report or financial statements but rather an opinion on matters related to the AGM agenda. The document length is short (1457 characters) and focuses on opinions and approvals related to AGM agenda items, consistent with AGM Information filings.
2022-04-21 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.